West Pharmaceutical Services, Inc.

NYSE:WST Lagerbericht

Marktkapitalisierung: US$24.4b

West Pharmaceutical Services Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

West Pharmaceutical Services wird ein jährliches Gewinn- und Umsatzwachstum von 11.1% bzw. 6.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 11.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 18.5% betragen.

Wichtige Informationen

11.1%

Wachstumsrate der Gewinne

11.40%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum18.6%
Wachstumsrate der Einnahmen6.5%
Zukünftige Eigenkapitalrendite18.50%
Analystenabdeckung

Good

Zuletzt aktualisiert31 Jul 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Narrative-Update • Jul 28

WST: High Value Injectable Demand And GLP 1 Exposure Will Drive Future Returns

The updated analyst price target for West Pharmaceutical Services has moved higher from $379 to about $404. This reflects analysts’ revised models that incorporate slightly lower revenue growth assumptions, a modest improvement in profit margin expectations, and a somewhat higher future P/E multiple.
Seeking Alpha • Jul 24

West Pharmaceutical Delivers Another Beat - But The Real Story Is The Mix Shift

Summary West Pharmaceutical Services delivered a strong 2Q26, beating on both revenue ($872.3M, +13.8% YoY) and EPS ($2.37, +$0.29 vs. consensus). WST raised full-year guidance to $3.345–$3.380B in sales and $8.85–$9.05 in EPS, reflecting confidence in sustained double-digit organic growth and margin expansion. High-Value Product components and biologics drove mix shift, with HVP now 49% of revenue and biologics up 29% organically, supporting durable margin gains. Valuation remains rich at 41x forward earnings, but the premium is justified by high-quality compounding, visible growth pillars, and conservative guidance. Read the full article on Seeking Alpha
Narrative-Update • Jul 13

WST: GLP 1 Injectables And On Body Delivery Moves Will Shape Future Returns

The analyst price target for West Pharmaceutical Services has been raised from $358.79 to $379.00, as analysts cite updated models that reflect healthy sector trends, exposure to GLP-1 related volumes, and continued support from recent Outperform ratings and target increases across the Street. Analyst Commentary Recent research commentary on West Pharmaceutical Services has focused on how the company is positioned within injectable drug delivery, its exposure to GLP-1 related volumes, and expectations for execution against updated financial models ahead of upcoming earnings events.
Narrative-Update • Jun 22

WST: Injectable Exposure And High Value Mix Will Shape Balanced Future Returns

Analysts have lifted their implied price target for West Pharmaceutical Services by about $6 to reflect updated fair value assumptions and ongoing confidence in injectable exposure, high value product momentum, and management execution highlighted in recent research. Analyst Commentary Recent research on West Pharmaceutical Services centers on how well the company is positioned in injectable markets and high value product categories, and how that ties into fair value and execution risk.
Narrative-Update • Jun 06

WST: Injectable Platforms And High Value Mix Will Support Future Earnings Power

Analysts have nudged their fair value estimate for West Pharmaceutical Services higher to about $352 per share, citing refreshed price targets around $325 to $375 and continued confidence in injectable driven growth and execution. Analyst Commentary Recent Street research has focused on how West Pharmaceutical Services is executing on growth in injectables and high value product categories, and what that could mean for valuation as price targets shift higher.
Narrative-Update • Apr 27

WST: Higher Margin Mix And Contract Services Expansion Will Support Earnings Power

Analysts have lifted the implied fair value estimate for West Pharmaceutical Services by about $11 to roughly $350, as a series of recent price target changes reflect updated assumptions around growth, margins and P/E multiples. Analyst Commentary Recent Street research on West Pharmaceutical Services shows a mix of upbeat and cautious messages as analysts recalibrate their models and price targets around updated assumptions for growth, margins and P/E multiples.
Narrative-Update • Feb 07

WST: Margin Resilience And Drug Delivery Portfolio Shift Will Support Earnings Power

Analysts have trimmed their price target on West Pharmaceutical Services by about US$7. This reflects updated assumptions around slightly softer revenue growth, a modestly higher discount rate, a small adjustment to future P/E expectations, and a marginally stronger profit margin outlook.
Narrative-Update • Jan 24

WST: 2026 Drug Delivery Focus And New Syringe Platform Will Support Earnings Power

Analysts have kept their fair value estimate for West Pharmaceutical Services steady at about $345.71 per share, with only slight tweaks to assumptions like the discount rate, long term revenue growth, profit margin, and future P/E, which together feed into their updated price target narrative. What's in the News West Pharmaceutical Services agreed to sell all manufacturing and supply rights for its SmartDose 3.5 mL On Body Delivery System, along with associated facilities, to AbbVie for total consideration of US$112.5 million at close, subject to working capital and other adjustments (Key Developments).
Narrative-Update • Jan 07

WST: Normalizing Markets And 2026 Visibility Will Support Earnings Power

Narrative update The updated analyst price target for West Pharmaceutical Services reflects a largely steady fair value near US$346. Analysts point to recent target hikes, higher EPS estimates and a constructive view on growth drivers into 2026 as key supports for the current valuation framework.
Narrative-Update • Dec 19

WST: Normalizing End Markets Will Support Stronger Earnings Base Into 2026

Analysts have modestly raised their price target on West Pharmaceutical Services to approximately $370, up from about $310. This reflects increased earnings estimates, a stronger setup into 2026, and improving, more stable end markets.
Narrative-Update • Dec 05

WST: Normalizing End Markets Will Support Strong Earnings Base Into 2026

Analysts have nudged their price target for West Pharmaceutical Services slightly higher to approximately $370, reflecting increased confidence in the company’s earnings power and growth drivers as market conditions normalize and set up favorably into 2026. Analyst Commentary Analyst views on West Pharmaceutical Services remain broadly constructive, with recent target hikes reflecting growing conviction that the company can sustain its earnings recovery as end markets normalize into 2026.
Narrative-Update • Nov 21

WST: Strong 2025 Outlook and Management Confidence Will Sustain Positive Momentum

West Pharmaceutical Services has seen its average analyst price target raised, with significant increases attributed to strong quarterly results, growing end market confidence, and a positive management outlook for 2026, according to analysts. Analyst Commentary Analysts have responded to West Pharmaceutical Services' recent performance and outlook with a range of observations tying directly to the company's valuation, execution, and growth prospects.
Narrative-Update • Nov 07

WST: Sustained Earnings Momentum Will Drive Confidence Into 2026

West Pharmaceutical Services has seen its average analyst price target rise from approximately $321 to $351. Analysts cite continued growth drivers and improved market conditions following a strong quarterly performance.
Narrative-Update • Oct 23

Analysts Raise Target for West Pharmaceutical Services Amid Strong Outlook and Upgraded Guidance

Analysts have increased their price target for West Pharmaceutical Services by $5 to $321. They cited the company's encouraging earnings call, management's confidence in future estimates, and stable end markets with improving investment sentiment.
Seeking Alpha • Mar 11

West Pharmaceutical: Remains A Strong Long-Term Prospect

Summary West Pharmaceutical Services has faced a challenging year, underperforming against the index, with declining volumes, margins, and returns, but remains a strong long-term investment. The company's high-value products segment, driven by GLP-1 medications and biologics, is expected to boost margins and returns significantly. Despite poor timing in share buybacks and management concerns, West's valuation suggests a potential 12.8% annual return, making it a buy. Key risks include management's strategic decisions and valuation, but the worst seems behind, with attractive prices for long-term growth. Read the full article on Seeking Alpha
Seeking Alpha • Feb 17

West Pharmaceuticals Takes A Plunge, But May Still Offer Opportunities

Summary The price of West Pharmaceutical Services plunged over 38% after it released its Q4 and FY 2024 earnings results on February 13. Shareholders, mostly institutional investors apparently, did not like the bottom-line results nor the uninspiring guidance for 2025. Still, West should not be overlooked, and there may be opportunities if the share price continues to rebound after a market overreaction. Read the full article on Seeking Alpha

Gewinn- und Umsatzwachstumsprognosen

NYSE:WST - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20283,8547787258719
12/31/20273,58770156879215
12/31/20263,37561543167415
6/30/20263,327565437662N/A
3/31/20263,221543458715N/A
12/31/20253,074494469755N/A
9/30/20253,018492379694N/A
6/30/20252,960488344677N/A
3/31/20252,896467307665N/A
12/31/20242,893493276653N/A
9/30/20242,876500322702N/A
6/30/20242,877525357752N/A
3/31/20242,929569386757N/A
12/31/20232,950593415777N/A
9/30/20232,927559420768N/A
6/30/20232,866519397707N/A
3/31/20232,884552410711N/A
12/31/20222,887586439724N/A
9/30/20222,909631388654N/A
6/30/20222,929686402675N/A
3/31/20222,881684382647N/A
12/31/20212,832662331584N/A
9/30/20212,681613341572N/A
6/30/20212,523519287500N/A
3/31/20212,326423307504N/A
12/31/20202,147346298473N/A
9/30/20202,037312272430N/A
6/30/20201,945286277420N/A
3/31/20201,888261N/A377N/A
12/31/20191,840242N/A367N/A
9/30/20191,792230N/A334N/A
6/30/20191,767229N/A314N/A
3/31/20191,745219N/A291N/A
12/31/20181,717207N/A289N/A
9/30/20181,711155N/A297N/A
6/30/20181,677151N/A284N/A
3/31/20181,627133N/A288N/A
12/31/20171,599151N/A263N/A
9/30/20171,566190N/A254N/A
6/30/20171,544176N/A246N/A
3/31/20171,535182N/A237N/A
12/31/20161,509144N/A219N/A
9/30/20161,487138N/A216N/A
6/30/20161,454102N/A216N/A
3/31/20161,42685N/A217N/A
12/31/20151,40096N/A212N/A
9/30/20151,39094N/A190N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: WSTDas prognostizierte Gewinnwachstum (11.1% pro Jahr) liegt über der Sparquote (3.7%).

Ertrag vs. Markt: WSTDie Erträge des Unternehmens (11.1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (16.9% pro Jahr).

Hohe Wachstumserträge: WSTDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: WSTDie Einnahmen des Unternehmens (6.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (12.9% pro Jahr).

Hohe Wachstumseinnahmen: WSTDie Einnahmen des Unternehmens (6.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: WSTDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (18.5%).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/08/19 20:39
Aktienkurs zum Tagesende2026/08/19 00:00
Gewinne2026/06/30
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

West Pharmaceutical Services, Inc. wird von 28 Analysten beobachtet. 15 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Lawrence MarshBarclays
Luke SergottBarclays
Curtis MoilesBNP Paribas